Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Support Care Cancer ; 29(1): 341-348, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32361831

ABSTRACT

PURPOSE: This study aimed to evaluate cancer-related weight loss (WL) after the start of first-line chemotherapy as a surrogate marker for cancer cachexia in patients with advanced gastric cancer. We investigated the incidence of WL and the relationship between WL and overall survival (OS) or adverse events. METHODS: We conducted a retrospective cohort study in 131 patients with advanced gastric cancer who received first-line systemic chemotherapy between September 1, 2010, and August 31, 2016, at Kurume University Hospital and Shizuoka Cancer Center Hospital. WL was defined in this study as weight loss of > 5% or weight loss of > 2% with a body mass index of < 20 kg/m2 within the last 6 months after the start of chemotherapy. RESULTS: Median age and median Eastern Cooperative Oncology Group performance status of the patients participating in this study were 68 years old and 0, respectively. Incidence of WL was 53% at the first 12 weeks after starting first-line chemotherapy, and increased to 88% after 48 weeks. Overall survival rates were significantly associated with WL at 12, 24, and 48 weeks. Appetite loss and fatigue were more frequent and more severe in patients with WL. CONCLUSION: WL was especially observed in more than half the patients within 12 weeks after starting chemotherapy. WL appeared to relate to adverse events or reduced survival. These results suggest the importance of monitoring WL or providing nutritional support at the beginning of chemotherapy.


Subject(s)
Antineoplastic Agents/adverse effects , Cachexia/chemically induced , Cachexia/epidemiology , Stomach Neoplasms/pathology , Weight Loss/physiology , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Body Mass Index , Female , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/drug therapy
2.
Adv Ther ; 37(12): 5010-5022, 2020 12.
Article in English | MEDLINE | ID: mdl-33067699

ABSTRACT

INTRODUCTION: This retrospective study focused on cancer cachexia in clinical practice. We evaluated the incidence of cancer cachexia and the relationship between cancer cachexia and overall survival (OS) or toxicities in patients with advanced colorectal cancer after undergoing first-line systemic chemotherapy. METHODS: We examined 150 patients with colorectal cancer who underwent first-line systemic chemotherapy between February 1, 2010 and August 31, 2016 at Shizuoka Cancer Center Hospital and Kurume University Hospital. Cancer cachexia was defined as > 5% weight loss or > 2% weight loss with a body mass index of < 20 kg/m2 within the past 6 months according to the European Palliative Care Research Collaborative criteria. RESULTS: One hundred patients from Shizuoka Cancer Center and 50 from Kurume University Hospital were registered. Median age and body mass index were 65 years (range 29-85) and 21.7 kg/m2 (14.8-32.5), respectively. Cumulative incidence of cancer cachexia was 50.7% at 24 weeks, and reached 91.3% over the whole study period. OS was significantly different between patients with and without cancer cachexia within 24 weeks after starting first-line treatment, although the onset of cancer cachexia within 24 weeks could not be considered as an independent prognostic factor for OS. Severe appetite loss and fatigue tended to occur more frequently in patients with cancer cachexia within 24 weeks. CONCLUSION: Cancer cachexia appears to have an onset in approximately half of patients with advanced colorectal cancer within 24 weeks after starting first-line treatment. Although causal relationships were controversial, the onset of cancer cachexia within 24 weeks tends to be related to worse outcomes. Thus, it would be better to monitor weight loss leading to cachexia in patients with advanced colorectal cancer, especially within 24 weeks after starting first-line chemotherapy. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry (UMIN000035002).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cachexia/diagnosis , Cachexia/epidemiology , Colorectal Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Body Mass Index , Cachexia/etiology , Cohort Studies , Female , Humans , Incidence , Male , Middle Aged , Palliative Care/statistics & numerical data , Retrospective Studies , Weight Loss
3.
Support Care Cancer ; 28(11): 5271-5279, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32103356

ABSTRACT

PURPOSE: Cachexia influences the patient's physical wellbeing and quality of life, and the patient's ability to tolerate their cancer therapies, especially cytotoxic chemotherapy. The purpose of this study was to investigate the frequency and timing of onset of cancer cachexia during chemotherapy and its association with prognosis and toxicity in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We performed a retrospective study in patients who underwent first-line chemotherapy after diagnosis of advanced PDAC between 6 June 2008 and 31 March 2017. Base cachexia (weight loss up to 6 months before starting first-line chemotherapy) and follow-up cachexia (after starting first-line chemotherapy) were defined as weight loss > 2% with a body mass index (BMI) < 20 kg/m2 or weight loss > 5%. RESULTS: A total of 150 patients were registered. The median age and BMI were 65 years and 21.7 kg/m2, respectively. Base cachexia occurred in 50% of patients. Follow-up cachexia occurred in 32% within 12 weeks of starting first-line chemotherapy, reaching 64% at 1 year. Overall survival was not significantly different between patients with and without follow-up cachexia, regardless of whether cancer cachexia occurred within 12, 24, or 48 weeks of starting first-line treatment. Appetite loss, fatigue, nausea, and diarrhea were more frequent in patients with follow-up cachexia than in those without follow-up cachexia. CONCLUSION: Follow-up cachexia had an early onset, but was not a prognostic factor for overall survival in patients with PDAC. Some adverse events tended to be more frequent in patients with follow-up cachexia than in those without follow-up cachexia.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cachexia/epidemiology , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/epidemiology , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Body Mass Index , Cachexia/diagnosis , Cachexia/etiology , Carcinoma, Pancreatic Ductal/complications , Carcinoma, Pancreatic Ductal/pathology , Disease Progression , Female , Humans , Incidence , Male , Middle Aged , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/pathology , Prevalence , Prognosis , Quality of Life , Retrospective Studies , Survival Analysis , Weight Loss/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...